(eye-lo-prost) ,


(trade name)


Therapeutic: vasodilators
Pharmacologic: prostacyclins
Pregnancy Category: C


Pulmonary arterial hypertension (WHO Group 1).


Dilates pulmonary and arterial vasculature.

Therapeutic effects

Improved exercise capacity.


Absorption: Unknown.
Distribution: Unknown.
Metabolism and Excretion: Any absorbed iloprost is metabolized.
Half-life: 20–30 min (plasma).

Time/action profile (improved exercise capacity)

Inhaln unknownunknownup to 2 hr


Contraindicated in: Hypersensitivity; Systolic BP <85 mm Hg; Lactation: Lactation.
Use Cautiously in: Concurrent use of drugs or coexisting medical conditions that may ↑ risk of syncope; COPD, asthma, or acute pulmonary infection (may ↑ risk of bronchospasm); Hepatic impairment (may need to ↑ dosing interval); Pediatric: Safety not established; Obstetric: Use only if maternal benefit outweighs fetal risk.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness
  • fainting
  • headache
  • insomnia

Ear, Eye, Nose, Throat

  • epistaxis


  • cough (most frequent)
  • bronchospasm
  • dyspnea
  • hemoptysis
  • wheezing


  • HF (life-threatening)
  • vasodilation (most frequent)
  • chest pain
  • hypotension
  • peripheral edema
  • supraventricular tachycardia


  • diarrhea
  • gingival bleeding
  • nausea
  • vomiting


  • renal failure


  • facial flushing


  • back pain
  • jaw-muscle spasm
  • muscle cramps


Drug-Drug interaction

↑ risk of hypotension with other vasodilators or diuretics.Risk of bleeding may be ↑ by anticoagulants.


Inhalation (Adults) 2.5 mcg initially, then 5 mcg/dose 6–9 times daily; not more than every 2 hr.

Hepatic Impairment

Inhalation (Adults) Child Pugh Class B or C—Consider ↑ dosing interval to every 3–4 hr.


Solution for inhalation: 10 mcg/mL ampules, 20 mcg/mL ampules

Nursing implications

Nursing assessment

  • Assess respiratory status (exercise intolerance, symptoms, deterioration) prior to and periodically during therapy.
  • Monitor vital signs prior to and throughout therapy. Do not administer if BP <85 mm Hg.
  • Assess for signs of pulmonary edema (dyspnea, jugular venous distension). If signs occur, discontinue iloprost immediately; may be a sign of pulmonary venous hypertension.

Potential Nursing Diagnoses

Activity intolerance (Indications)
Ineffective breathing pattern (Indications)


  • Avoid iloprost contact with skin or eyes, or oral ingestion.
  • Inhalation: Prepare medication by one ampule of iloprost into Prodose ADD System or I-neb ADD system medication chamber immediately before use. Do not mix with other medications. Administer 6–9 times/day during waking hours, according to patient's needs and tolerability. Discard solution remaining in chamber after inhalation. Follow manufacturer's instructions for cleaning components after administration of each dose.

Patient/Family Teaching

  • Instruct patient in use of iloprost and Prodose ADD System or I-neb ADD system, frequency, ampule dispensing, and cleaning of equipment. See manufacturer's instructions. Advise patient that inhalation intervals should not be less than 2 hr, but acute benefits of medication may not last 2 hr.
  • May cause dizziness and fainting due to hypotension. Caution patient to change positions slowly to minimize orthostatic hypotension.

Evaluation/Desired Outcomes

  • Improved exercise tolerance, decrease in symptoms of pulmonary edema, and lack of deterioration in patients with pulmonary arterial hypertension.


a brand name for ILOPROST TROMETAMOL.
References in periodicals archive ?
Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins (naturally occurring molecules that cause blood vessels to dilate).
as the Ventavis Inhalant Solution under exclusive contract with Schering AG, which markets the drug in Europe and Australia.
LONDON -- Iloprost (also called Ventavis, Ilomedin) is artificial prostacylin (PGI2) that is specifically indicated for the treatment of pulmonary arterial hypertension.
Dickinson led the filing of the NDA and label negotiations for CoTherix's initial product, Ventavis (iloprost) Inhalation Solution.
The various drugs used to treat PAH are: Tracleer (bosentan), Letairis (ambrisentan), Remodulin (treprostinil), Ventavis (iloprost), Revatio (sildenafil), Adcirca (tadalafil), Tyvaso (inhaled treprostinil), and Veletri (epoprostenol).
The current branded drugs are Lipitor (atorvastatin), Plavix (clopidogrel), Ventavis (iloprost) and Crestor (rosuvastatin).
Actelion's new Ventavis formulation Receives Approval from US
The history behind Bayer's Ventavis inhalation solution, launched in 2004, is an example of how a company which is not involved in the development of a marketed drug is able to capitalise on its success.
The drugs used in the treatment of PAH are Tracleer (bosentan), Letairis (ambrisentan), Remodulin (treprostinil), Ventavis (iloprost), Revatio (sildenafil), Adcirca (tadalafil), Tyvaso (inhaled treprostinil) and Veletri (epoprostenol).
Ventavis (iloprost) is an inhaled formulation of iloprost, approved for the treatment of pulmonary arterial hypertension.
Ventavis (iloprost) from CoTherix, an inhalation solution for the treatment of PAH in patients with NYHA Class III or IV symptoms, launched in March 2005.
Actelion Receives FDA Approval for New Ventavis Formulation II-104